Latest & greatest articles for amlodipine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amlodipine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amlodipine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amlodipine

21. Tekamlo, (aliskiren/amlodipine)

Tekamlo, (aliskiren/amlodipine) Drug Approval Package: Tekamlo (aliskiren/amlodipine) NDA #022545 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Tekamlo, (aliskiren/amlodipine) 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg and 300 mg/10 mg Tablets Company: Novartis Pharmaceuticals Corporation Application No.: 022545 Approval Date: 08/26/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF

2010 FDA - Drug Approval Package

22. Amturnide (amlodipine/aliskiren/hydrochlorothiazide)

Amturnide (amlodipine/aliskiren/hydrochlorothiazide) Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Amturnide (amlodipine/aliskiren/hydrochlorothiazide) 150/5/12.5 mg, 300/5/12.5 mg, 300/5/25 mg, 300/10/12.5 mg and 300/10/25 mg Tablets Company: Novartis Pharmaceuticals Application No.: 200045 Approval Date: 12/21/2010 Persons with disabilities having problems

2010 FDA - Drug Approval Package

23. Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide)

Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Drug Approval Package: TRIBENZOR (olmesartan medoxomil and amlodipine) NDA #200175 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - TRIBENZOR (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Tablets Company: Daiichi Sankyo, Inc. Application No.: 200175 Approval Date: 07/23/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2010 FDA - Drug Approval Package

24. Amlodipin + Atorvastatin

Amlodipin + Atorvastatin 2010. DAR No 2: Amlodipin + Atorvastatin - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 2: Amlodipin + Atorvastatin DAR No 2: Amlodipin + Atorvastatin Content tools Share it A combination that makes no sense The combination of amlodipin-atorvastatin is indicated in the prevention of cardiovascular events in hypertensive patients with three other concomitant risk factors, and with normal or mildly elevated (...) cholesterol levels. The efficacy of statins to reduce cardiovascular risk in primary prevention in patients with normal cholesterol levels has not been sufficiently demonstrated. The addition of atorvastatin in patients under treatment with amlodipin in the indication mentioned increases the risk of adverse reactions and the cost of treatment with no clear health benefits. Therefore this combination is not justified. Enviar comentario You can send us a comment or suggestion and we will respond to most

2010 Drug and Therapeutics Bulletin of Navarre (Spain)

25. Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis

Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

26. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials

Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

27. Twynsta - telmisartan / amlodipine

Twynsta - telmisartan / amlodipine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged. 22 July 2010 EMA/576613/2010 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report TWYNSTA International Nonproprietary Name (...) : telmisartan / amlodipine Procedure No. EMEA/H/C/001224 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Table of contents Page 1. Background information on the procedure 3 1.1. Submission of the dossier 3 1.2. Steps taken for the assessment of the product 4 2. Scientific discussion 5 2.1. Introduction 5 2.2. Quality aspects 5 2.3. Non-clinical aspects 8 2.4. Clinical aspects 18 2.5. Clinical efficacy 27 2.6. Clinical safety 44 2.7

2010 European Medicines Agency - EPARs

28. Twynsta (telmisartan/amlodipine)

Twynsta (telmisartan/amlodipine) Drug Approval Package: Twynsta (telmisartan/amlodipine) NDA #022401 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Twynsta (telmisartan/amlodipine) 40/5, 40/10, 80/5, 80/10 mg Tablets Company: Boehringer Ingelheim Pharmaceuticals, Inc. Application No.: 022401 Approval Date: 10/16/2009 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2009 FDA - Drug Approval Package

29. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared (...) with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, Wedel H, Jonsson B, Anglo-Scandinavian Cardiac Outcomes Trial investigators Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2009 NHS Economic Evaluation Database.

30. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea

Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine (...) and atorvastatin for the primary prevention of cardiovascular disease in Korea Liew D, Park HJ, Ko SK Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of a single-tablet fixed-dose combination of amlodipine

2009 NHS Economic Evaluation Database.

31. Copalia HCT - amlodipine / valsartan / hydrochlorothiazide

Copalia HCT - amlodipine / valsartan / hydrochlorothiazide European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: mail@emea.europa.eu http://www.emea.europa.eu Doc.Ref: EMEA/CHMP/471143/2009 ASSESSMENT REPORT FOR Copalia HCT International Nonproprietary Name: amlodipine besylate / valsartan / hydrochlorothiazide Procedure No. EMEA/H/C/001159 Assessment Report as adopted (...) new fixed combination products. The applicant applied for the following indication: “Treatment of essential hypertension. Copalia HCT is indicated as replacement therapy in patients whose blood pressure is adequately controlled on amlodipine, valsartan and hydrochlorothiazide (HCT) used as individual or combination therapies”. Information on Paediatric requirements Pursuant to Article 7, the application included an EMEA Decision P/14/2009 for the following condition: • Essential hypertension

2009 European Medicines Agency - EPARs

32. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen (PubMed)

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden.A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects.Primary care.Patients with moderate hypertension and three or more additional risk (...) applied by NICE and in the Swedish National Board of Health and Welfare's Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol-based regimen in the population studied.

Full Text available with Trip Pro

2008 EvidenceUpdates

33. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. (PubMed)

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting-enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus (...) a thiazide diuretic.In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.The baseline characteristics

2008 NEJM

34. An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy

An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy An Asian regional analysis of cost (...) -effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy Annemans L, Demarteau N, Hu S, Lee T J, Morad Z, Supaporn T, Yang W C, Palmer A J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

Full Text available with Trip Pro

2008 NHS Economic Evaluation Database.

35. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

36. Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension

Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension Article Text

2007 Evidence-Based Medicine (Requires free registration)

37. Irbesartan and amlodipine in the treatment of patients with microalbuminuria, hypertension and type 2 diabetes in Taiwan: a modelling projection over 25 years

Irbesartan and amlodipine in the treatment of patients with microalbuminuria, hypertension and type 2 diabetes in Taiwan: a modelling projection over 25 years Irbesartan and amlodipine in the treatment of patients with microalbuminuria, hypertension and type 2 diabetes in Taiwan: a modelling projection over 25 years Irbesartan and amlodipine in the treatment of patients with microalbuminuria, hypertension and type 2 diabetes in Taiwan: a modelling projection over 25 years Yang W C, Hwang S J (...) , Annemans L, Ray J A, Roze S, Valentine W J, Palmer A J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the long-term cost-effectiveness of early irbesartan, late irbesartan, amlodipine, and standard

2007 NHS Economic Evaluation Database.

38. Copalia - amlodipine / valsartan

Copalia - amlodipine / valsartan ©EMEA 2007 1/2929291 SCIENTIFIC DISCUSSION 1. Introduction The proper management and control of blood pressure in hypertension patients, and the impact it has on associated morbidity and mortality rates, has been the focus of many new hypertension observational studies and clinical trials. These trials have demonstrated that more aggressive blood pressure lowering will reduce the complications associated with hypertension. As a result of this data, international (...) . Therefore, the applicant was asked for a commitment to perform a separate study in elderly patients (see: follow-up measures). • Adverse events A literature search for the combination therapy did not provide any unknown AE or AES. Adverse events by primary system organ class generally show comparable incidences between the valsartan/amlodipine group, the monotherapy groups and the placebo groups. The most frequently occurring AE in the total valsartan/amlodipine group was peripheral edema. It occurred

2007 European Medicines Agency - EPARs

39. Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients

Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients Article Text

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

40. Amlodipine besylate/ atorvastatin calcium

Amlodipine besylate/ atorvastatin calcium Common Drug Review CEDAC Meeting – April 19, 2006 Page 1 of 1 Notice of CEDAC Final Recommendation – May 17, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (Caduet ™ – Pfizer Canada Inc.) Description: Caduet ™ is a fixed dose combination of amlodipine and atorvastatin and is approved for use in patients for whom treatment with both amlodipine and atorvastatin is appropriate, specifically (...) , patients at cardiovascular risk. Dosage Forms: Tablets containing amlodipine/atorvastatin in the following combinations: 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 mg and 10/80 mg. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that Caduet ™ be listed for patients who have been titrated to a stable combination of the separate components, amlodipine and atorvastatin. Reasons for the Recommendation: 1. There were no randomized controlled trials (RCTs

2006 Canadian Agency for Drugs and Technologies in Health - Common Drug Review